5IDL
 
 | | Crystal structure of the germline-targeting HIV-1 gp120 engineered outer domain, eOD-GT8 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Germline-targeting HIV-1 gp120 engineered outer domain, eOD-GT8 | | Authors: | Julien, J.P, Ereno-Orbea, J, Jardine, J.G, Schief, W.R, Wilson, I.A. | | Deposit date: | 2016-02-24 | | Release date: | 2016-10-05 | | Last modified: | 2023-09-27 | | Method: | X-RAY DIFFRACTION (2.9 Å) | | Cite: | HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen.
Science, 351, 2016
|
|
5VKJ
 | | Crystal structure of human CD22 Ig domains 1-3 | | Descriptor: | B-cell receptor CD22, GLYCEROL, alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose | | Authors: | Julien, J.P, Ereno-Orbea, J, Sicard, T. | | Deposit date: | 2017-04-21 | | Release date: | 2017-10-04 | | Last modified: | 2024-04-03 | | Method: | X-RAY DIFFRACTION (2.12 Å) | | Cite: | Molecular basis of human CD22 function and therapeutic targeting.
Nat Commun, 8, 2017
|
|
5VKM
 | | Crystal structure of human CD22 Ig domains 1-3 in complex with alpha 2-6 sialyllactose | | Descriptor: | B-cell receptor CD22, GLYCEROL, N-acetyl-alpha-neuraminic acid-(2-6)-beta-D-galactopyranose, ... | | Authors: | Julien, J.P, Ereno-Orbea, J, Sicard, T. | | Deposit date: | 2017-04-21 | | Release date: | 2017-10-04 | | Last modified: | 2024-10-23 | | Method: | X-RAY DIFFRACTION (2.2 Å) | | Cite: | Molecular basis of human CD22 function and therapeutic targeting.
Nat Commun, 8, 2017
|
|
2P8L
 | | Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELLELDKWASLWN | | Descriptor: | gp41 peptide, nmAb 2F5, heavy chain, ... | | Authors: | Julien, J.P, Bryson, S, Pai, E.F. | | Deposit date: | 2007-03-22 | | Release date: | 2007-05-15 | | Last modified: | 2011-07-13 | | Method: | X-RAY DIFFRACTION (2.44 Å) | | Cite: | Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
J.Mol.Biol., 384, 2008
|
|
2P8M
 | | Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELLELDKWASLWN in new crystal form | | Descriptor: | gp41 peptide, nmAb 2F5, heavy chain, ... | | Authors: | Julien, J.P, Bryson, S, Pai, E.F. | | Deposit date: | 2007-03-22 | | Release date: | 2007-05-15 | | Last modified: | 2011-07-13 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
J.Mol.Biol., 384, 2008
|
|
3IDG
 | |
2F5B
 | | CRYSTAL STRUCTURE OF FAB' FROM THE HIV-1 NEUTRALIZING ANTIBODY 2F5 IN COMPLEX WITH ITS GP41 EPITOPE | | Descriptor: | PROTEIN (ANTIBODY 2F5 (HEAVY CHAIN)), PROTEIN (ANTIBODY 2F5 (LIGHT CHAIN)), PROTEIN (GP41 EPITOPE) | | Authors: | Bryson, S, Julien, J.P, Hynes, R.C, Pai, E.F. | | Deposit date: | 1999-04-09 | | Release date: | 2003-07-08 | | Last modified: | 2024-10-16 | | Method: | X-RAY DIFFRACTION (2 Å) | | Cite: | Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications.
J.Virol., 83, 2009
|
|
8DNN
 | | Crystal structure of neutralizing antibody 80 in complex with SARS-CoV-2 receptor binding domain | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 80 FAB HEAVY CHAIN, 80 FAB LIGHT CHAIN, ... | | Authors: | Muthuraman, K, Kucharska, I, Ivanochko, D, Julien, J.P. | | Deposit date: | 2022-07-11 | | Release date: | 2023-05-24 | | Last modified: | 2024-10-23 | | Method: | X-RAY DIFFRACTION (3.12 Å) | | Cite: | A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivo.
Sci Transl Med, 15, 2023
|
|
9B76
 | |
9B74
 | |
9B75
 | |
9B7B
 | |
8U70
 | |
8US8
 | |
7K9Z
 | | Crystal structure of SARS-CoV-2 receptor binding domain in complex with the Fab fragments of neutralizing antibodies 298 and 52 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 298 Fab Heavy Chain, 298 Fab Light Chain, ... | | Authors: | Newton, J.C, Kucharska, I, Rujas, E, Cui, H, Julien, J.P. | | Deposit date: | 2020-09-29 | | Release date: | 2020-10-28 | | Last modified: | 2024-10-23 | | Method: | X-RAY DIFFRACTION (2.95 Å) | | Cite: | Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers.
Nat Commun, 12, 2021
|
|
2F5A
 | | CRYSTAL STRUCTURE OF FAB' FROM THE HIV-1 NEUTRALIZING ANTIBODY 2F5 | | Descriptor: | PROTEIN (ANTIBODY 2F5 (HEAVY CHAIN)), PROTEIN (ANTIBODY 2F5 (LIGHT CHAIN)) | | Authors: | Bryson, S, Julien, J.P, Hynes, R.C, Pai, E.F. | | Deposit date: | 1999-04-08 | | Release date: | 2003-07-15 | | Last modified: | 2024-11-06 | | Method: | X-RAY DIFFRACTION (2.05 Å) | | Cite: | Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications.
J.Virol., 83, 2009
|
|
7RLV
 | |
7RLX
 | |
7RM0
 | |
7RM1
 | |
7RLZ
 | |
7RM3
 | | Antibody 2E10.E9 in complex with P. vivax CSP peptide ANGAGNQPGANGAGNQPGANGAGGQAA | | Descriptor: | 2E10.E9 Fab heavy chain, 2E10.E9 Fab light chain, ACETATE ION, ... | | Authors: | Kucharska, I, Ivanochko, D, Julien, J.P. | | Deposit date: | 2021-07-26 | | Release date: | 2022-01-26 | | Last modified: | 2024-10-30 | | Method: | X-RAY DIFFRACTION (2.68 Å) | | Cite: | Structural basis of Plasmodium vivax inhibition by antibodies binding to the circumsporozoite protein repeats.
Elife, 11, 2022
|
|
6PHF
 | |
6PHC
 | |
6PHB
 | |
